Last reviewed · How we verify
various neoadjuvant therapies
At a glance
| Generic name | various neoadjuvant therapies |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (PHASE2, PHASE3)
- PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study (NA)
- Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (NA)
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (PHASE2)
- Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial (PHASE2)
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (PHASE2)
- Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
- Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- various neoadjuvant therapies CI brief — competitive landscape report
- various neoadjuvant therapies updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI